Ginkgo Bioworks Expects To Add 100-120 New Cell Programs To Cell Engineering Platform In 2024; Expects 2024 Total Revenue Of $215M-$235M, Est $279.546M
Portfolio Pulse from Benzinga Newsdesk
Ginkgo Bioworks anticipates adding 100-120 new cell programs to its cell engineering platform in 2024, with expected total revenue ranging between $215M-$235M, which is below the estimated $279.546M.
February 29, 2024 | 10:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ginkgo Bioworks expects to significantly expand its cell engineering platform in 2024 but forecasts lower-than-expected revenues of $215M-$235M, against estimates of $279.546M.
The announcement of adding a significant number of new cell programs indicates a strong growth trajectory for Ginkgo Bioworks' cell engineering platform. However, the projected revenue for 2024 being lower than the estimated figures could lead to negative investor sentiment in the short term, potentially impacting the stock price negatively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100